We are pleased to announce that our VP of CMC, Friedmund Bachmann, and Scientist Alejandro Puchol will be presenting at the upcoming Congress of the European Association of Nuclear Medicine (EANM23) in Vienna, taking place from September 9-13, 2023.

1. “Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG Bispecific Antibody Demonstrates Efficacy in Murine Models of Cancer.”

2. “Preclinical PET imaging with 89Zr-labelled oxMIF-specific antibody – ON102 – delineates subcutaneous tumors in colorectal murine models.”